Incorporating Fusion-Guided Biopsy to Practice

MK-5684/ODM-208 is a selective CYP11A1 inhibitor currently under investigation in the phase 3 OMAHA1 and OMAHA2a trials.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Earlier this year, the FDA cleared an investigational new drug application for SYNC-T SV-1022.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

"Using this as an adjunctive test after PSA screening will give physicians more information to help decide if their patient should undergo a prostate biopsy or not,” says M. Eric Hyndman, MD, PhD, FRCSC.

The fast track designation for BNT324/DB-1311 is supported by safety and efficacy data from an ongoing phase 1/2 trial of the ADC in patients with advanced/metastatic solid tumors.